Royal Bank of Canada Forecasts Strong Price Appreciation for AdaptHealth (NASDAQ:AHCO) Stock

AdaptHealth (NASDAQ:AHCO) had its price target upped by Royal Bank of Canada from $11.00 to $14.00 in a research note published on Wednesday,Benzinga reports. They currently have an outperform rating on the stock.

A number of other research analysts have also commented on the stock. UBS Group dropped their price objective on shares of AdaptHealth from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Thursday, February 13th. Canaccord Genuity Group dropped their price objective on shares of AdaptHealth from $14.00 to $13.00 and set a “buy” rating on the stock in a research note on Wednesday, November 6th. Robert W. Baird dropped their price objective on shares of AdaptHealth from $16.00 to $14.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. Finally, Truist Financial lifted their target price on shares of AdaptHealth from $12.00 to $14.00 and gave the company a “buy” rating in a report on Wednesday. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $13.80.

AdaptHealth Trading Up 2.6 %

NASDAQ AHCO opened at $11.38 on Wednesday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 1.00 and a current ratio of 1.24. The firm has a market cap of $1.53 billion, a PE ratio of -6.90, a P/E/G ratio of 1.08 and a beta of 1.12. AdaptHealth has a one year low of $8.35 and a one year high of $11.90. The firm’s fifty day moving average is $9.92 and its two-hundred day moving average is $10.23.

Institutional Trading of AdaptHealth

Hedge funds and other institutional investors have recently made changes to their positions in the company. Intech Investment Management LLC boosted its holdings in shares of AdaptHealth by 223.2% in the third quarter. Intech Investment Management LLC now owns 59,650 shares of the company’s stock valued at $670,000 after acquiring an additional 41,196 shares in the last quarter. Victory Capital Management Inc. boosted its holdings in AdaptHealth by 727.4% during the third quarter. Victory Capital Management Inc. now owns 141,507 shares of the company’s stock worth $1,589,000 after buying an additional 124,404 shares in the last quarter. Royce & Associates LP boosted its holdings in AdaptHealth by 13.5% during the third quarter. Royce & Associates LP now owns 777,405 shares of the company’s stock worth $8,730,000 after buying an additional 92,740 shares in the last quarter. Barclays PLC boosted its holdings in AdaptHealth by 361.3% during the third quarter. Barclays PLC now owns 181,240 shares of the company’s stock worth $2,034,000 after buying an additional 141,949 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its holdings in AdaptHealth by 39.7% during the third quarter. Principal Financial Group Inc. now owns 543,744 shares of the company’s stock worth $6,106,000 after buying an additional 154,434 shares in the last quarter. Hedge funds and other institutional investors own 82.67% of the company’s stock.

AdaptHealth Company Profile

AdaptHealth Corp., together with its subsidiaries, sells home medical equipment (HME), medical supplies, and home and related services in the United States. The company provides sleep therapy equipment, supplies, and related services, such as CPAP and bi-PAP services to individuals suffering from obstructive sleep apnea; medical devices and supplies, including continuous glucose monitors and insulin pumps for the treatment of diabetes; HME to patients discharged from acute care and other facilities; oxygen and related chronic therapy services in the home; and other HME devices and supplies on behalf of chronically ill patients with wound care, urological, incontinence, ostomy, and nutritional supply needs.